Cookie Preference

This website uses cookies to improve user experience. Please select an option.  Privacy Policy

No cookies except for those necessary for technical reasons are set.

Startups 2019

Emerging Startup

ImmuCon

Prof. Matthias Mack

Innovation & Business Idea

SLE is a chronic inflammatory disease that can affect virtually any organ and imposes a threefold increased risk of death due to SLE maifestations and infections. Current therapy consists of long term treatment with glucocorticoids, anti-malarials and immunosuppressive drugs. The only biologic (Belimumab) has low activity against SLE. All of these drugs, especially glucocorticoids have considerable side effects. There is clearly a high need for more specific, more effective, and less toxic therapies of SLE. In recent years IL-3 was identified as an important regulator and inducer of autoimmunity and inflammation. IL-3 strongly acts on plasmacytoid dendritic cells, basophils, B cells, monocytes and endothelial cells, all of which contribute to autoimmunity by production of interferon, activation of B cells, production of autoantibodies, release of proinflammatory cytokines, and recruitment of leukocytes. Thus IL-3 is stronlgy involved in all relevant pathways of SLE. In addition, we have demonstrated that IL-3 is markedly over-expressed in patients with active SLE, rheumatoid arthritis and psoriatic arthritis. Moreover, IL-3 expression correlates with disease activity and was not reduced by currently available drugs. Blockade or knock-out of IL-3 markedly improved disease activity in animal models of lupus nephritis, arthritis, encephalitis and myocarditis. In a sepsis model, IL-3-deficient mice did not develop the typical cytokine storm and were protected from death. In contrast, overexpression or injection of IL-3 aggravated disease activity in mice and induced a pronounced inflammation with polyarthritis in rhesus monkeys. Under basal conditions, IL-3 KO-mice have no overt phenotype and no hematopoietic abnormalities.


Customers / Target Market

The prevalence of SLE is 0.122%. About 30% of SLE patients are not well controlled with currently available drugs. Assuming a 25% market penetration and costs of €40.000 / patient / year a market potential of up to €4 B could be reached. Additional indications include rheumatoid arthritis and psoriatic arthritis.


Competitors

There are no competitors that develop antibodies against IL-3.


Intellectual Property Status

ImmuCon will be able to obtain a strong patent portfolio of 5 patents from the Univeristy of Regensburg covering IL-3 antibodies and inhibition of IL-3 for treatment of SLE and RA.


Development Status & Future Steps

We have developed a fully humanized antibody against IL-3 that blocks human IL-3 with high potency. In contrast to commercially available antibodies, our antibody is able to block the heavily glycosylated primary human IL-3 obtained from patients. The antibody has been extensively characterized and is suitable for GMP-production and clinical testing.


Exit Strategy

ImmuCon will perform the preclinical and clinical development until prove of concept in a phase II clinical trial in patients with SLE and subsequently licence or sell the products to a pharmaceutical company for further development.


Team Description

ImmuCon will have a core management team (CEO, CSO, CMO) as well as experienced scientists and study nurses that will coordinate all work packages (Company Team). This team will be supported by a University Team providing scientific and medical know-how and performing lab work. Thus, ImmuCon has access to a fully equipped and well established lab infrastructure with experienced personnel.


Financing Need

The preclinical and clinical development including proof of concept in a clinical phase IIa study is estimated to cost about €22 M and to take about 5 years.


Searching for

Commercial Partner, Funding, Collaboration

 

ImmuCon